Remove 2014 Remove FDA Remove Packaging
article thumbnail

ICH Q6B for Analytics

PharmTech

Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substances: Quality Issues (revision 1) (May 22, 2014). With their technical and methodological improvements, advanced techniques provide valuable information on overall product mass profiles.

Dosage 52
article thumbnail

Pharmaceutical Compounding Calculations, Part Two–Bulk Drugs

PharmTech

FDA guidance documents illustrate labeling salt drugs and associated active moieties. The secondary label will specify the Drug ZA-ion amount per capsule and the equivalent Drug Z-salt amount consistent with FDA labeling guidance. Additional mole calculations are needed only for drug-name labeling per FDA guidance ( Figure 5b above).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The unsustainability of clinical trials and need for transformative change

Pharmaceutical Technology

Trials intended for FDA submission must include patients representative of the US population While clinical trials can be conducted in multiple regions throughout the world in order to increase the pool of eligible patients, the proportion of US patients in applications submitted to the US FDA has been declining.

article thumbnail

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

The US Food and Drug Administration (FDA) approved Amgen’s Blincyto (blinatumomab), the first bispecific T-cell engager (BiTE), in 2014 for adults with Ph- R/R B-ALL, with its label expanded in 2017 to include Ph+ and paediatric cases. Give your business an edge with our leading industry insights.

article thumbnail

eMDR System Enhancements

The FDA Law Blog

Manufacturers who submit reports via the FDA Electronic Submissions Gateway are being advised to update their systems by this time. Background FDA first introduced the final rule and guidance on eMDR in 2014 , which we blogged about here. Either way, the information is transmitted to FDA via the ESG. b)(1)(iii).

article thumbnail

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

Pharmaceutical Technology

Broadening uses and secured full approvals Since its first approval in September 2014, Keytruda has achieved blockbuster status on the market. Earlier in March, the FDA shared a draft guidance on how to run clinical trials for the accelerated approval of cancer drugs.

article thumbnail

Case Study 2 – The Journey Leading to an Approved NDA

Impact Pharmaceutical Services

Over the next year, IMPACT authored the following documents for the client: Pre-NDA meeting package. Subsequent to the on-time submission of the NDA, IMPACT was asked to author the client’s FDA Advisory Committee Briefing Document. 5 clinical study reports. and 2.7.4), and the Clinical Overview (Module 2.5).